Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Syros Pharmaceuticals (SYRS): Deerfield Management Discloses Position

Page 1 of 14

James E. Flynn‘s Deerfield Management has disclosed a stake in Syros Pharmaceuticals Inc (NASDAQ:SYRS), a biotechnology company recently gone public. According to a recent filing with the Securities and Exchange Commission, the fund holds 2.09 million shares, which account for approximately 8.97% of Syros Pharmaceuticals’ common stock.

James Flynn Deerfield Management

Syros Pharmaceuticals Inc (NASDAQ:SYRS) has developed a gene control platform that analyzes the DNA of patients in order to identify new targets for gene control medicines. The company went public at the end of June in an IPO priced at $12.50 per share, although initially it aimed between $14 and $16 a share. Syros Pharmaceuticals offered 4.6 million shares and options for an additional 600,000 shares for their underwriters, totaling gross proceeds of $57.5 million. The company will use the funds to finance further development of its SY-1425 candidate for the treatment of acute myelogenous leukemia and myelodysplastic syndrome, and the SY-1365 candidate designed to treat acute leukemia.

No other hedge funds followed by Insider Monkey have yet disclosed a position in Syros Pharmaceuticals Inc (NASDAQ:SYRS).

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Deerfield Mgmt 0 628,566 0 628,566 628,566 2.69%
Deerfield Management Company 0 2,095,220 0 2,095,220 2,095,220 8.97%
Deerfield Mgmt III 0 1,466,654 0 1,466,654 1,466,654 6.28%
Deerfield Special Situations Fund 0 628,566 0 628,566 628,566 2.69%
Deerfield Private Design Fund III 0 1,466,654 0 1,466,654 1,466,654 6.28%
James E. Flynn 0 2,095,220 0 2,095,220 2,095,220 8.97%

Page 1 of 14 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. ) *
Syros Pharmaceuticals, Inc.

(Name of Issuer)
Common Stock, par value $0.001 per share

(Title of Class of Securities)
87184Q107

(CUSIP Number)
July 6, 2016

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
(Page 1 of 11 Pages)
__________________
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Syros Pharmaceuticals Inc.
Trade (SYRS) Now!
Page 1 of 14
Loading Comments...